Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 5, 2012, Pages 820-828

  Isakova, Tamara ^a   Xie, Huiliang ^a   Barchi Chung, Allison ^a   Smith, Kelsey ^a   Sowden, Nicole ^a   Epstein, Michael ^b   Collerone, Gina ^b   Keating, Leigh ^b   Jüppner, Harald ^b   Wolf, Myles ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE;

ADULT; AGED; ARTICLE; CALCIUM EXCRETION; CALCIUM URINE LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MEAL; METABOLITE;

AGED; CALCITRIOL; CALCIUM; CIRCADIAN RHYTHM; DIETARY SUPPLEMENTS; FECES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; POSTPRANDIAL PERIOD; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS; VITAMINS;

EID: 84860732514     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.11721111     Document Type: Article

References (28)

1. Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370-1378, 2011
2. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71: 31-38, 2007
3. Nickolas TL, Leonard MB, Shane E: Chronic kidney disease and bone fracture: A growing concern. Kidney Int 74: 721-731, 2008
4. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011
5. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro O M, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393-4408, 2011
6. Isakova T, Gutierrez O, Shah A, Castaldo L, Holmes J, Lee H, Wolf M: Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 19: 615-623, 2008
7. Drinka PJ, Krause PF, Nest LJ, Goodman BM: Determinants of parathyroid hormone levels in nursing home residents. J AmMed Dir Assoc 8: 328-331, 2007
8. Stein MS, Scherer SC, Walton SL, Gilbert RE, Ebeling PR, Flicker L, Wark JD: Risk factors for secondary hyperparathyroidism in a nursing home population. Clin Endocrinol (Oxf) 44: 375-383, 1996
9. Reichel H, Deibert B, Geberth S, Schmidt-Gayk H, Ritz E: Frusemide therapy and intact parathyroid hormone plasma concentrations in chronic renal insufficiency. Nephrol Dial Transplant 7: 8-15, 1992
10. Coe FL, Canterbury JM, Firpo JJ, Reiss E: Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. J Clin Invest 52: 134-142, 1973
11. Isakova T, Anderson CA, Leonard MB, Xie D, Gutiérrez OM, Rosen LK, Theurer J, Bellovich K, Steigerwalt SP, Tang I, Anderson AH, Townsend RR, He J, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. Nephrol Dial Transplant 26: 1258-1265, 2011
12. Cunningham J, Locatelli F, Rodriguez M: Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6: 913-921, 2011
13. Berndt T, Thomas LF, Craig TA, Sommer S, Li X, Bergstralh EJ, Kumar R: Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc Natl Acad Sci USA 104: 11085-11090, 2007
14. Worcester EM, Gillen DL, Evan AP, Parks JH, Wright K, Trumbore L, Nakagawa Y, Coe FL: Evidence that postprandial reduction of renal calcium reabsorption mediates hypercalciuria of patients with calcium nephrolithiasis. Am J Physiol Renal Physiol 292: F66-F75, 2007
15. el-Hajj Fuleihan G, Klerman EB, Brown EN, Choe Y, Brown EM, Czeisler CA: The parathyroid hormone circadian rhythm is truly endogenous-a general clinical research center study. J Clin Endocrinol Metab 82: 281-286, 1997
16. Spiegel DM, Brady K: Calciumbalance in normal individuals and in patientswith chronic kidney disease on low- and high-calcium diets [published online ahead of print February 1, 2012]. Kidney Int doi:10.1038/ki.2011.490
17. Clarkson EM, Eastwood JB, Koutsaimanis KG, de Wardener HE: Net intestinal absorption of calcium in patients with chronic renal failure. Kidney Int 3: 258-263, 1973
18. National Kidney Foundation: K/DOQI clinical practice guidelines for bonemetabolismand disease in chronic kidney disease. Am J Kidney Dis 42[Suppl 3]: S1-S201, 2003
19. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435, 2004
20. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205-2215, 2005
21. Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, Yamashita T, Fukumoto S, Shimada T: Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 78: 975-980, 2010
22. Ferrari SL, Bonjour JP, Rizzoli R: Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90: 1519-1524, 2005
23. Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, Jüppner H, Salusky IB: Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 79: 112-119, 2011
24. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic KidneyDisease-Mineral and BoneDisorder (CKD-MBD). Kidney Int Suppl 113: S1-S130, 2009
25. Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272-2279, 2003
26. Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, Olear E, Gundberg CM: Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: Circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab 95: E352-E357, 2010
27. Vervloet MG, van Ittersum FJ, Büttler RM, Heijboer AC, Blankenstein MA, ter Wee PM: Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol 6: 383-389, 2011
28. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B: Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 19: 1613-1619, 2008